Surfing the NASH Tsunami

Why Nash Drug Trials Fail: A Thoughtful, Challenging Theory - Ep 34

November 11, 2020 HEP Dynamics LLC Season 1 Episode 34
Surfing the NASH Tsunami
Why Nash Drug Trials Fail: A Thoughtful, Challenging Theory - Ep 34
Chapters
Surfing the NASH Tsunami
Why Nash Drug Trials Fail: A Thoughtful, Challenging Theory - Ep 34
Nov 11, 2020 Season 1 Episode 34
HEP Dynamics LLC

Prof. Dr. Jörn M. Schattenberg joins the Surfers to discuss his recent article in Expert Opinion on Investigational Drugs dissecting recent drug trial failures.

Prof. Dr. Jörn M. Schattenberg joins Stephen, Donna, Louise and Roger to discuss his recent article "The Nonalcoholic Steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successes." The discussion started with lessons from failed trials, focusing on the importance of utilizing Phase 2 trials to test hypotheses and establish appropriate targets. From there, Surfers went on to discuss commercial and patient-focused definitions of what makes a clinical trial successful.

Show Notes

Prof. Dr. Jörn M. Schattenberg joins the Surfers to discuss his recent article in Expert Opinion on Investigational Drugs dissecting recent drug trial failures.

Prof. Dr. Jörn M. Schattenberg joins Stephen, Donna, Louise and Roger to discuss his recent article "The Nonalcoholic Steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successes." The discussion started with lessons from failed trials, focusing on the importance of utilizing Phase 2 trials to test hypotheses and establish appropriate targets. From there, Surfers went on to discuss commercial and patient-focused definitions of what makes a clinical trial successful.